表紙
市場調查報告書
商品編碼
973899

Epoetin alfa:生物相似藥的洞察(2020年)

Epoetin alfa- Biosimilar Insight, 2020

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 60 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供生物相似藥:Epoetin alfa的相關調查,提供15家公司以上的企業和20家公司以上的成藥及開發平台藥物相關全面的洞察,含臨床、非臨床階段的產品的市售及開發平台的藥物簡介,各產品類型、階段、給藥途徑、分子類型的治療方法的評估等資訊。

本報告刊載的企業

  • Zydus Cadila
  • Wockhardt
  • UBI Pharma
  • Sun Pharmaceutical Industires
  • Stada Arzneimittel
  • Sedico
  • Sandoz
  • Reliance Life Sciences
  • Pfizer (Hospira)
  • Duopharma
  • Nanogen
  • Medice Arzneimittel Putter
  • LG Chem
  • Hexal
  • Emcure
  • Dragon Pharmaceutical
  • Claris Lifesciences
  • Blau Farmaceutica
  • Biosidus
  • Biocon
  • Biocad
  • Apotex
  • Amega Bitoech
  • Johnson & Johnson
  • PanGen

本報告刊載的主要產品

  • EPO
  • Wepox
  • UB-851
  • Ceriton
  • Silapo
  • Epoetin 2000 I.U.
  • Binocrit
  • Epostim
  • ReliPoietin
  • Retacrit
  • Erisa (PDA10)
  • Nanokine
  • Abseamed
  • Espogen
  • Epoetin alfa Hexal
  • Epofer
  • BR 05001
  • Epotin
  • Eritromax
  • Epoimmun
  • Erypro
  • Erythropoietin alfa biosimilar
  • APO-EPO
  • Recombinant erythropoietin
  • Epoetin alfa - ProLease
  • PDA 10

目錄

第1章 主要洞察

第2章 概述

第3章 摘要整理

  • 概要
  • 生技藥品的基礎。
  • 學名藥和生物相似藥
  • 生物相似藥的經濟學:低價格的承諾,實際的費用
  • 患者需要了解哪些有關生物相似藥的訊息

第4章 生物相似藥的法規預測

  • 北美
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
  • 其他地區
    • 巴西
    • 墨西哥
    • 阿根廷
    • 沙烏地阿拉伯

第5章 Epoetin alfa(參考產品:Epogen)

  • 產品概要
  • 適應症
  • 作用機制
  • 投藥和管理
  • 劑量和優勢
  • 用量變更
  • 合成途徑
  • 藥理學
  • 藥效學
  • 藥物動力學
  • 副作用
  • 產品的概述
  • 開發里程碑

第6章 法規的里程碑

  • 核准
  • 研究開發
  • 臨床試驗資訊
  • 安全性和有效性

第7章 新機會

第8章 生物相似藥的評估

  • 各產品類型的評估
  • 各給藥途徑的評估
  • 各分子類型的評估
  • 各銷售的評估

第9章 企業簡介

  • PanGen Biotech
  • Reliance Life Sciences

第10章 比較形勢:各企業

第11章 競爭情形

    • 概要
    • 市場佔有率分析
    • 競爭模式

第12章 市場成長要素

第13章 市場障礙

第14章 SWOT分析

第15章 附錄

第16章 參考文件

第17章 DelveInsight的服務內容

第18章 免責聲明

第19章 關於DelveInsight

目錄

DelveInsight's, "Epoetin alfa- Biosimilar Insight, 2020," report provides comprehensive insights about 15+ companies and 20+ marketed and pipeline drugs in Epoetin alfa Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Epoetin alfa Understanding

Epoetin alfa: Overview

Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein manufactured by recombinant DNA technology. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin. Epogen (epoetin alfa) injection for intravenous or subcutaneous administration is formulated as a sterile, clear, colorless liquid in vials in multiple formulations.

Epoetin alfa Biosimilars: Drugs Chapters

This segment of the Epoetin alfa report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, Phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Epoetin alfa Biosimilars: Marketed Drugs

  • Binocrit: Sandoz

Binocrit (epoetin alfa) is a prescription medicine that stimulates the bone marrow to produce red blood cells. In April 2016, Sandoz announced that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit's (epoetin alfa) nephrology indication.

  • Epoimmun: Biosidus

Epoimmun is a synthetic form of human erythropoietin, used to treat anemia. Biosidus recombinant human erythropoietin is their flagship product which is obtained by mass cell culture of genetically modified mammalian cells.

Further product details are provided in the report:

Epoetin alfa Biosimilars: Emerging Drugs

  • UB 851: UBI Pharma

UB-851 is a recombinant human EPO biosimilar. Its highly glycosylated structure, with sialic acid content being the key factor for the in vivo half-life of EPO, makes the product development challenging. Unlike small molecule drugs, biosimilars have complicated structures and large molecular weights. The bioactivity, safety, and efficacy of biosimilars are closely related to the manufacturing process, which is very difficult to replicate.

Further product details are provided in the report:

Epoetin alfa: Therapeutic Assessment

This segment of the report provides insights about the different Epoetin alfa biosimilars segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Epoetin alfa

There are approx. 15+ key companies which are developing the therapies for Epoetin alfa.

  • Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like:

  • Marketed stage products
  • Late stage products (BLA Filed and Phase III)
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Epoetin alfa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

  • Subcutaneous
  • Intravenous
  • Molecule Type

Products have been categorized under various Molecule types such as:

  • Monoclonal antibodies
  • Peptide
  • Protein
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Epoetin alfa: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Epoetin alfa biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Epoetin alfa biosimilar drugs.

Report Highlights:

  • The companies and academics are working to assess challenges and seek opportunities that could influence Epoetin alfa R&D. The therapies under development are focused on novel approaches to treat/improve Epoetin alfa.
  • In May 2018, Pfizer announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT (epoetin alfa-epbx), a biosimilar to Epogen and Procrit (epoetin alfa)1, for all indications of the reference product. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) to be approved in the US.
  • In August 2018, Stada announced that it is increasing its presence in the biosimilar sphere by becoming the majority shareholder in Bioceuticals, a venture capital-funded organization created by Stada to carry out its biosimilar programs.

Epoetin alfa Biosimilars Report Insights

  • Epoetin alfa Biosimilar Pipeline Analysis
  • Therapeutic Assessment
  • Sales Assessment
  • Unmet Needs
  • Impact of Drugs

Epoetin alfa Biosimilar Report Assessment

  • Marketed Product profiles
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Sales Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Epoetin alfa Biosimilars?
  • How many Epoetin alfa biosimilars are developed by each company?
  • How many emerging biosimilars are in mid-stage, and late-stage?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Epoetin alfa biosimilars therapeutics?
  • What are the clinical studies going on for Epoetin alfa biosimilars and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Zydus Cadila
  • Wockhardt
  • UBI Pharma
  • Sun Pharmaceutical Industires
  • Stada Arzneimittel
  • Sedico
  • Sandoz
  • Reliance Life Sciences
  • Pfizer (Hospira)
  • Duopharma
  • Nanogen
  • Medice Arzneimittel Putter
  • LG Chem
  • Hexal
  • Emcure
  • Dragon Pharmaceutical
  • Claris Lifesciences
  • Blau Farmaceutica
  • Biosidus
  • Biocon
  • Biocad
  • Apotex
  • Amega Bitoech
  • Johnson & Johnson
  • PanGen

Key Products

  • EPO
  • Wepox
  • UB-851
  • Ceriton
  • Silapo
  • Epoetin 2000 I.U.
  • Binocrit
  • Epostim
  • ReliPoietin
  • Retacrit
  • Erisa (PDA10)
  • Nanokine
  • Abseamed
  • Espogen
  • Epoetin alfa Hexal
  • Epofer
  • BR 05001
  • Epotin
  • Eritromax
  • Epoimmun
  • Erypro
  • Erythropoietin alfa biosimilar
  • APO-EPO
  • Recombinant erythropoietin
  • Epoetin alfa - ProLease
  • PDA 10

Table of Contents

1. Key Insights

2. Epoetin alfa Biosimilars: Snapshot

3. Executive Summary

  • 3.1. Overview
  • 3.2. The Basics of Biologics.
  • 3.3. Biosimilars are not the Same as Generic Drugs
  • 3.4. Economics of Biosimilars - the Promise of Lower Prices, but at What Cost?
  • 3.5. What Patients Need to Know About Biosimilars

4. Regulatory Outlook For Biosimilars

  • 4.1. North America
    • 4.1.1. US
    • 4.1.2. Canada
  • 4.2. Europe
  • 4.3. Asia Pacific
    • 4.3.1. China
    • 4.3.2. India
    • 4.3.3. Japan
    • 4.3.4. South Korea
    • 4.3.5. Australia
  • 4.4. Rest Of The World
    • 4.4.1. Brazil
    • 4.4.2. Mexico
    • 4.4.3. Argentina
    • 4.4.4. Saudi Arabia

More Countries would be added in the final report

5. Epoetin alfa (Reference Product: Epogen)

  • 5.1. Product Overview
  • 5.2. Indications
  • 5.3. Mechanism of Action
  • 5.4. Dosage and Administration
  • 5.5. Dosage and Strengths
  • 5.6. Dose Modification
  • 5.7. Route of Synthesis
  • 5.8. Pharmacology
  • 5.9. Pharmacodynamics
  • 5.10. Pharmacokinetics
  • 5.11. Adverse Reactions
  • 5.12. Product Snapshot
  • 5.13. Development Milestones

6. Regulatory Milestones

  • 6.1. Approvals
  • 6.2. Research and Development
  • 6.3. Clinical Trials Information
  • 6.4. Safety and Efficacy

7. Epogen Biosimilar: Emerging Opportunities

8. Epoetin alfa: Biosimilars Assessment

  • 8.1. Assessment by Product Type
  • 8.2. Assessment by Route of Administration
  • 8.3. Assessment by Molecule type
  • 8.4. Sales Assessment

9. Epoetin alfa Biosimilars Profiles: By Company

    • 9.1.1. PanGen Biotech
      • 9.1.1.1. Erisa (PDA10): PanGen Biotech/Duopharma
      • 9.1.1.1.1. Product Information
      • 9.1.1.1.2. Research and Development
      • 9.1.1.1.3. Other Development Activities
      • 9.1.1.1.4. General Description Table
    • 9.1.2. Reliance Life Sciences
      • 9.1.2.1. Epostim: Reliance Life Sciences
      • 9.1.2.1.1. Product Information
      • 9.1.2.1.2. Research and Development
      • 9.1.2.1.3. Other Development Activities
      • 9.1.2.1.4. General Description Table
      • 9.1.2.2. ReliPoietin: Reliance Life Sciences
      • 9.1.2.2.1. Product Information
      • 9.1.2.2.2. Research and Development
      • 9.1.2.2.3. Other Development Activities
      • 9.1.2.2.4. General Description Table

More Companies and products would be added in the final report

10. Epoetin alfa Biosimilars: Comparative Landscape: By Company

11. Epoetin alfa Biosimilars: Competitive Landscape

    • 11.1.1. Overview
    • 11.1.2. Market Share Analysis
    • 11.1.3. Competitive Scenario
      • 11.1.3.1. Product Launches and approval
      • 11.1.3.2. Partnerships, Collaborations and Agreements
      • 11.1.3.3. Acquisitions
      • 11.1.3.4. Expansions
      • 11.1.3.5. Patent Expiration of Biologics

More information would be added in the final report

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix

  • 15.1. Research Methodology
    • 15.1.1. Coverage
    • 15.1.2. Secondary Research

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1: Total Products for Non Muscle Invasive Bladder Cancer
  • Table 2: Late Stage Products
  • Table 3: Mid Stage Products
  • Table 4: Early Stage Products
  • Table 5: Pre-clinical & Discovery Stage Products
  • Table 6: Assessment by Product Type
  • Table 7: Assessment by Stage and Product Type
  • Table 8: Assessment by Route of Administration
  • Table 9: Assessment by Stage and Route of Administration
  • Table 10: Assessment by Molecule Type
  • Table 11: Assessment by Stage and Molecule Type
  • Table 12: Inactive Products

List of Figures

  • Figure 1: Total Products for Non Muscle Invasive Bladder Cancer
  • Figure 2: Late Stage Products
  • Figure 3: Mid Stage Products
  • Figure 4: Early Stage Products
  • Figure 5: Preclinical and Discovery Stage Products
  • Figure 6: Assessment by Product Type
  • Figure 7: Assessment by Stage and Product Type
  • Figure 8: Assessment by Route of Administration
  • Figure 9: Assessment by Stage and Route of Administration
  • Figure 10: Assessment by Molecule Type
  • Figure 11: Assessment by Stage and Molecule Type
  • Figure 12: Inactive Products